Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Formycon AG (DE:FYB)
XETRA:FYB
FYB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€37.65 - €64.40
Previous CloseN/A
Volume3.47K
Average Volume (3M)18.08K
Market Cap
€969.78M
Enterprise ValueN/A
Total Cash (Recent Filing)13.97M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)13.6
Beta0.84
Next Earnings
Apr 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.03
Shares Outstanding17,664,427
10 Day Avg. Volume19,414
30 Day Avg. Volume18,080
Standard Deviation0.13
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)30.34
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€88.28Price Target Upside64.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Formycon AG News
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe European Commission has granted central marketing authorization for FYB203, a biosimilar referencing Eylea, which is valid in all European Economic Area countries.
Market PositioningFYB202 would be among the first wave of Stelara biosimilars entering the U.S. market, positioning it well to seize market shares.
Strategic PartnershipsTeva Pharmaceuticals has entered a licensing agreement for the semi-exclusive commercialization of FYB203 in major parts of Europe and Israel.
Bears Say
Competitive MarketEylea is currently the standard of care for wet AMD and other retinal disorders and achieved global sales of approximately $9B in 2023.
Financial PerformanceRoyalty and other revenue was slightly below projections for the first nine months of 2024.
Revenue ShareFormycon will participate in the mid-single-digit to low-double-digit percentage range in all payment streams to Klinge from the commercialization of FYB203.
---
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.27% Public Companies and
Individual Investors
FYB FAQ
What was Formycon AG’s price range in the past 12 months?
Formycon AG lowest stock price was €37.65 and its highest was €64.40 in the past 12 months.
What is Formycon AG’s market cap?
Formycon AG’s market cap is €969.78M.
When is Formycon AG’s upcoming earnings report date?
Formycon AG’s upcoming earnings report date is Apr 24, 2025 which is in 76 days.
How were Formycon AG’s earnings last quarter?
Formycon AG released its earnings results on Nov 28, 2024. The company reported €0.03 earnings per share for the quarter, beating the consensus estimate of -€0.03 by €0.06.
Is Formycon AG overvalued?
According to Wall Street analysts Formycon AG’s price is currently Undervalued.
Does Formycon AG pay dividends?
Formycon AG does not currently pay dividends.
What is Formycon AG’s EPS estimate?
Formycon AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Formycon AG have?
Formycon AG has 17,664,427 shares outstanding.
What happened to Formycon AG’s price movement after its last earnings report?
Formycon AG reported an EPS of €0.03 in its last earnings report, beating expectations of -€0.03. Following the earnings report the stock price went up 2.987%.
Which hedge fund is a major shareholder of Formycon AG?
Currently, no hedge funds are holding shares in DE:FYB
---
Formycon AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€88.28 (64.70% Upside)
€88.28 (64.70% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.79%
12-Months-Change
Fundamentals
Return on Equity
12.73%
Trailing 12-Months
Asset Growth
3.82%
Trailing 12-Months
Company Description
Formycon AG
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
---
FYB Stock 12 Month Forecast
Average Price Target
€88.28
▲(64.70% Upside)
Technical Analysis
BB Biotech
―
Biotest
―
Evotec
―
Fresenius Medical Care AG & Co. KGaA
―
Porsche Automobil Holding
―
Best Analysts Covering FYB
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
-0.76%
reiterated a buy rating 26 days ago
Copying Nicolas Pauillac's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of -0.76% per trade.
---